标题
The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo
作者
关键词
-
出版物
BLOOD
Volume 122, Issue 7, Pages 1192-1202
出版商
American Society of Hematology
发表日期
2013-06-15
DOI
10.1182/blood-2013-03-484642
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- An Opportunistic Infection Associated With Ruxolitinib, a Novel Janus Kinase 1,2 Inhibitor
- (2013) Nicholas G. Wysham et al. CHEST
- JAK2 Inhibitors for Myelofibrosis: Why are They Effective in Patients with and Without JAK2V617F Mutation?
- (2012) Fabio P. S. Santos et al. Anti-Cancer Agents in Medicinal Chemistry
- Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors
- (2012) Anna Yarilina et al. ARTHRITIS AND RHEUMATISM
- Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides
- (2012) Stefanie Andrea Erika Held et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis
- (2012) Naresh Punwani et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon
- (2011) Sanna Rosengren et al. ANNALS OF THE RHEUMATIC DISEASES
- Regulation of dectin-1-mediated dendritic cell activation by peroxisome proliferator-activated receptor-gamma ligand troglitazone
- (2011) G. Kock et al. BLOOD
- Janus kinase/signal transducer and activator of transcription 3 signaling pathway is crucial in chemokine production from hepatocytes infected by dengue virus
- (2011) Yi-Ting Tsai et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Preclinical Evaluation of Local JAK1 and JAK2 Inhibition in Cutaneous Inflammation
- (2011) Jordan S. Fridman et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- IFN-γ activated JAK1 shifts CD40-induced cytokine profiles in human antigen-presenting cells toward high IL-12p70 and low IL-10 production
- (2010) Michael Conzelmann et al. BIOCHEMICAL PHARMACOLOGY
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
- Bioluminescence imaging allows measuring CD8 T cell function in the liver
- (2010) Dirk Stabenow et al. HEPATOLOGY
- Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell–licensed DCs
- (2010) Verena Semmling et al. NATURE IMMUNOLOGY
- Loss of Jak2 Selectively Suppresses DC-Mediated Innate Immune Response and Protects Mice from Lethal Dose of LPS-Induced Septic Shock
- (2010) Jixin Zhong et al. PLoS One
- Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion
- (2009) B. Jahrsdorfer et al. BLOOD
- Proteasome inhibition overcomes the resistance of renal cell carcinoma cells against the PPARγ ligand troglitazone
- (2009) K. von Schwarzenberg et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
- Jak3 Is Involved in Dendritic Cell Maturation and CCR7-Dependent Migration
- (2009) Ana Rivas-Caicedo et al. PLoS One
- Generation of antigen-specific CTL responses using RGS1 mRNA transfected dendritic cells
- (2008) Frank Grünebach et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started